TrialCompass™ TCL
Back to trials
Phase 1RecruitingPriority 4 · Lower priorityNCT06699771

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

ClinicalTrials.gov

Plain-language summary

This trial is testing GCC2005 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 19 Years to 80 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

GCC2005 (DRUG): CAR-NK Cell Therapy | Cyclophosphamide (DRUG): Lymphodepleting chemotherapy | Fludarabine (DRUG): Lymphodepleting chemotherapy

  • GCC2005, Cyclophosphamide, Fludarabine

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

NCT06699771

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing GCC2005 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join

  • Age 19 Years to 80 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

GCC2005 (DRUG): CAR-NK Cell Therapy | Cyclophosphamide (DRUG): Lymphodepleting chemotherapy | Fludarabine (DRUG): Lymphodepleting chemotherapy

Drugs / treatments: GCC2005, Cyclophosphamide, Fludarabine

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 53 patients

Primary endpoint: Safety: Frequency, severity, and persistence of AEs and AEs Grade 3 or higher; To determine MTD and RP2D: Safety(based on frequency, severity, and persistence of AEs and AEs Grade 3 or higher), efficacy (based on ORR) and pharmacokinetics

Ages: 19 Years to 80 Years

Start date: 2025-03-07 | Est. completion: 2027-08

Locations

0 US sites · 3 total

Contact

HyeSung Jeon | hs_jeon@gccorp.com | +82-31-260-9059

Sponsor: GC Cell Corporation (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06699771

Prepared using TrialCompass (trialcompass.com) on August 18, 2026. For informational purposes only. Always discuss with your healthcare team.